OSUR Logo

OraSure Technologies, Inc. (OSUR) 

NASDAQ
Market Cap
$324.74M
Sector
Healthcare
Industry
Medical—Instruments & Supplies
Rank in Sector
660 of 776
Rank in Industry
44 of 48

Largest Insider Buys in Sector

OSUR Stock Price History Chart

OSUR Stock Performance

About OraSure Technologies, Inc.

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick …

Insider Activity of OraSure Technologies, Inc.

Over the last 12 months, insiders at OraSure Technologies, Inc. have bought $0 and sold $194,219 worth of OraSure Technologies, Inc. stock.

On average, over the past 5 years, insiders at OraSure Technologies, Inc. have bought $390,761 and sold $107,749 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 100,000 shares for transaction amount of $492,810 was made by McGrath Kenneth J (Chief Financial Officer) on 2023‑05‑30.

List of Insider Buy and Sell Transactions, OraSure Technologies, Inc.

2023-12-19SaleChief Product Officer
24,129
0.0327%
$8.05$194,219-35.02%
2023-08-15SaleSVP Finance & CAO
1,758
0.0024%
$6.50$11,427-7.68%
2023-05-30PurchaseChief Financial Officer
100,000
0.1373%
$4.93$492,810+22.40%
2022-08-26Purchase
50,000
0.0689%
$4.00$200,000+28.00%
2022-08-25Purchase
6,000
0.0083%
$4.19$25,138+22.20%
2022-08-17Purchase
2,200
0.0031%
$4.39$9,658+17.91%
2022-08-12Purchase
12,000
0.0163%
$4.49$53,916+10.96%
2020-12-23SaleEVP & BU Lead - Molecular
10,000
0.0141%
$11.76$117,600-9.40%
2019-05-14PurchasePresident and CEO
2,000
0.0032%
$8.56$17,120-7.44%
2019-05-13PurchaseSVP & General Counsel
20,000
0.0325%
$8.55$170,974-5.05%
2019-05-10PurchaseCFO
20,000
0.032%
$9.03$180,627-11.69%
2019-04-01SalePresident and CEO
33,334
0.0474%
$9.71$323,768-26.92%
2018-08-27Saledirector
16,000
0.0262%
$16.29$260,640-31.51%
2018-02-16SaleEVP & BU Lead - Molecular
20,000
0.0215%
$11.98$239,600-12.28%
2018-02-15Saledirector
46,666
0.056%
$13.15$613,495-10.94%
2018-02-15SaleEVP & BU Lead - Molecular
20,000
0.0218%
$11.95$239,040-10.94%
2017-11-07Purchasedirector
5,000
0.0085%
$14.23$71,164+21.88%
2017-10-04SalePresident & CEO
45,846
0.0763%
$23.00$1.05M-24.60%
2017-09-29SalePresident & CEO
50,000
0.0834%
$22.55$1.13M-23.29%
2017-08-31SaleSee Remarks
18,224
0.0222%
$14.95$272,412-14.60%

Insider Historical Profitability

<0.0001%
McGrath Kenneth JChief Financial Officer
285512
0.3829%
$4.3610+22.4%
TANG STEPHEN S PHDPresident and CEO
119960
0.1609%
$4.3616<0.0001%
Celano Michael
111823
0.15%
$4.3624<0.0001%
SPAIR RONALD HCOO & CFO
109066
0.1463%
$4.36118<0.0001%
LANCASTER RONNY B
104782
0.1405%
$4.3655<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$77.5M17.0412.6M-0.16%-$125,712.15<0.01
The Vanguard Group$33.27M7.315.41M+1.88%+$612,367.80<0.01
Dimensional Fund Advisors$27.8M6.114.52M+15.72%+$3.78M0.01
Camber Capital Management Lp$26.14M5.754.25M0%+$00.92
Neuberger Berman$24.96M5.494.06M+29.73%+$5.72M0.02
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.